222 related articles for article (PubMed ID: 20056651)
1. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
3. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
Prasad CP; Mirza S; Sharma G; Prashad R; DattaGupta S; Rath G; Ralhan R
Life Sci; 2008 Aug; 83(9-10):318-25. PubMed ID: 18662704
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
6. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
7. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.
Dolled-Filhart M; McCabe A; Giltnane J; Cregger M; Camp RL; Rimm DL
Cancer Res; 2006 May; 66(10):5487-94. PubMed ID: 16707478
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
10. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
[TBL] [Abstract][Full Text] [Related]
11. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
Faratian D; Munro A; Twelves C; Bartlett JM
Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
[TBL] [Abstract][Full Text] [Related]
12. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours.
Wong SC; Lo SF; Lee KC; Yam JW; Chan JK; Wendy Hsiao WL
J Pathol; 2002 Feb; 196(2):145-53. PubMed ID: 11793365
[TBL] [Abstract][Full Text] [Related]
13. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer.
Gonzalez MA; Pinder SE; Wencyk PM; Bell JA; Elston CW; Nicholson RI; Robertson JF; Blamey RW; Ellis IO
J Pathol; 1999 Apr; 187(5):523-9. PubMed ID: 10398116
[TBL] [Abstract][Full Text] [Related]
15. [Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications].
Niu LG; He JJ; Wang K; Zhang W; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2237-40. PubMed ID: 19923077
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
[TBL] [Abstract][Full Text] [Related]
17. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Lim SC; Lee MS
Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
